The FOXC2-512C>T variant is associated with hypertriglyceridaemia and increased serum C-peptide in Danish Caucasian glucose-tolerant subjects

被引:16
作者
Yanagisawa, K
Larsen, LH
Andersen, G
Drivsholm, T
Cederberg, A
Westergren, R
Borch-Johnsen, K
Pedersen, O
Enerbäck, S
Hansen, T
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Hagedorn Res Inst, DK-2820 Gentofte, Denmark
[3] Copenhagen Univ Hosp, Inst Prevent & Hlth, Danish Epidemiol Sci Ctr, Copenhagen, Denmark
[4] Res Ctr Prevent & Hlth, Copenhagen, Denmark
[5] Univ Gothenburg, Dept Biochem Med, Gothenburg, Sweden
[6] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark
关键词
FOXC2; genetics; single nucleotide polymorphism; Type; 2; diabetes; hypertriglyceridaemia; association study;
D O I
10.1007/s00125-003-1213-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis. The transcription factor FOXC2 plays a key role in adipocyte differentiation and the FOXC2 gene is a candidate gene for Type 2 diabetes, obesity and dyslipidaemia. We investigated whether the FOXC2 -512C>T promoter variant is associated with Type 2 diabetes or its intermediary phenotypes in glucose tolerant subjects. Methods. The variant was genotyped using PCR-RFLP in 705 unrelated Type 2 diabetic patients, 505 unrelated glucose-tolerant control subjects and 219 glucose-tolerant offspring of Type 2 diabetic probands. Results. The frequency of the T-allele was 58% (95% CI 56-61%) and 59% (56-62%) among the Type 2 diabetic patients and the unrelated glucose-tolerant control subjects, respectively (p=0.6). Among the glucose-tolerant subjects, the T-allele carriers had higher fasting serum triglyceride (p=0.03), fasting serum C-peptide concentrations (p=0.009) and insulinogenic index (p=0.04). Furthermore, in glucose-tolerant women, the waist-to-hip ratio was significantly higher in carriers of the T-allele. Conclusion/interpretation. Our data suggest that the FOXC2 -512C>T variant is not associated with Type 2 diabetes. However, among glucose-tolerant subjects the variant is associated with hypertriglyceridaemia and increased fasting serum C-peptide.
引用
收藏
页码:1576 / 1580
页数:5
相关论文
共 10 条
[1]  
ALBERTI KGM, 1999, DEFINITION DIAGNOS 1, P1
[2]   FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance [J].
Cederberg, A ;
Gronning, LM ;
Ahrén, B ;
Taskén, K ;
Carlsson, P ;
Enerbäck, S .
CELL, 2001, 106 (05) :563-573
[3]   Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus [J].
Hansen, T ;
Ambye, L ;
Grarup, N ;
Hansen, L ;
Echwald, SM ;
Ferrer, J ;
Pedersen, O .
DIABETOLOGIA, 2001, 44 (10) :1330-1334
[4]   Five years on the wings of fork head [J].
Kaufmann, E ;
Knochel, W .
MECHANISMS OF DEVELOPMENT, 1996, 57 (01) :3-20
[5]   Genetic variation in the human winged helix/forkhead transcription factor gene FOXC2 in Pima Indians [J].
Kovacs, P ;
Lehn-Stefan, A ;
Stumvoll, M ;
Bogardus, C ;
Baier, LJ .
DIABETES, 2003, 52 (05) :1292-1295
[6]   Systematic search for single nucleotide polymorphisms in the FOXC2 gene - The absence of evidence for the association of three frequent single nucleotide polymorphisms and four common haplotypes with Japanese type 2 diabetes [J].
Osawa, H ;
Onuma, H ;
Murakami, A ;
Ochi, M ;
Nishimiya, T ;
Kato, K ;
Shimizu, I ;
Fujii, Y ;
Ohashi, J ;
Makino, R .
DIABETES, 2003, 52 (02) :562-567
[7]   Combined analysis of genome scans of Dutch and Finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q [J].
Pajukanta, P ;
Allayee, H ;
Krass, KL ;
Kuraishy, A ;
Soro, A ;
Lilja, HE ;
Mar, R ;
Taskinen, MR ;
Nuotio, I ;
Laakso, M ;
Rotter, JI ;
de Bruin, TWA ;
Cantor, RM ;
Lusis, AJ ;
Peltonen, L .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (04) :903-917
[8]   FOXC2 mRNA expression and a 5′ untranslated region polymorphism of the gene are associated with insulin resistance [J].
Ridderstråle, M ;
Carlsson, E ;
Klannemark, M ;
Cederberg, A ;
Kösters, C ;
Tornqvist, H ;
Storgaard, H ;
Vaag, A ;
Enerbäck, S ;
Groop, L .
DIABETES, 2002, 51 (12) :3554-3560
[9]  
Rosen ED, 2000, GENE DEV, V14, P1293
[10]  
Valet P, 2002, J LIPID RES, V43, P835